Runben Biotechnology Future Growth
Future criteria checks 4/6
Runben Biotechnology is forecast to grow earnings and revenue by 22.2% and 24.2% per annum respectively. EPS is expected to grow by 20.9% per annum. Return on equity is forecast to be 16.6% in 3 years.
Key information
22.2%
Earnings growth rate
20.9%
EPS growth rate
| Personal Products earnings growth | 21.1% |
| Revenue growth rate | 24.2% |
| Future return on equity | 16.6% |
| Analyst coverage | Good |
| Last updated | 19 Aug 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,182 | 500 | N/A | 482 | 5 |
| 12/31/2025 | 1,725 | 388 | N/A | 380 | 7 |
| 12/31/2024 | 1,354 | 318 | N/A | 300 | 6 |
| 6/30/2024 | 1,198 | 287 | 254 | 265 | N/A |
| 3/31/2024 | 1,048 | 240 | 248 | 258 | N/A |
| 12/31/2023 | 1,033 | 226 | 239 | 253 | N/A |
| 9/30/2023 | 998 | 209 | 188 | 216 | N/A |
| 12/31/2022 | 856 | 160 | 125 | 165 | N/A |
| 12/31/2021 | 582 | 121 | -13 | 139 | N/A |
| 12/31/2020 | 443 | 95 | 29 | 87 | N/A |
| 12/31/2019 | 279 | 36 | 43 | 62 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603193's forecast earnings growth (22.2% per year) is above the savings rate (2.9%).
Earnings vs Market: 603193's earnings (22.2% per year) are forecast to grow slower than the CN market (23.2% per year).
High Growth Earnings: 603193's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603193's revenue (24.2% per year) is forecast to grow faster than the CN market (13.3% per year).
High Growth Revenue: 603193's revenue (24.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603193's Return on Equity is forecast to be low in 3 years time (16.6%).